Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|AKT1 wild-type||clear cell renal cell carcinoma||sensitive||Everolimus + RX-0201||Phase Ib/II||Actionable||In a Phase I/II trial, RX-0201 and Afinitor (everolimus) combination therapy resulted in stable disease in 40% (2/5) of patients with metastatic clear cell renal carcinoma (J Clin Oncol 34, 2016 (suppl 2S; abstr 550)).||detail...|
|PubMed Id||Reference Title||Details|
|Archexin, a novel AKT-1–specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data.||Full reference...|